Amy Schumer speaks out about impact of new weight loss medication after revealing Ozempic left her ‘bedridden'
Amy Schumer has provided fans with a comical update on her weight loss journey.
The I Feel Pretty star said she tried Ozempic a few years ago and the side effects left her 'bedridden'. Ozempic, a type of medication often prescribed to people with type 2 diabetes, is known to have all sorts of side effects.
Often people can react in different ways, but the drug can cause nausea, vomiting, diarrhea, and stomach pain, according to Ozempic's website.
For Schumer, she tried it almost three years ago and despite losing 30 pounds, it made her 'so sick'.
'I have this gene, GDF15, which makes you extremely prone to nausea, which is why I was so sick during my pregnancy,' the 45-year-old said on The Howard Stern Show in January.
'So, I tried Ozempic almost three years ago and I was like, bedridden. I was like, vomiting — and then you have no energy. But other people take it and they're all good. God bless them.'
'I tried it and I was vomiting and I'm in bed and my son's like, 'Can you play tag?' I'm like, 'I can't.' I was shrivelling,' she added. 'I couldn't lift my head off the pillow, so what's the point?'
Now, as well as Ozempic, the film star has opened up about her Mounjaro journey too, which happens to be available via the NHS for certain individuals.
Ozempic isn't approved for weight loss; however, semaglutide is under the name Wegovy.
Mounjaro is a weekly injection consisting of tirzepatide. It is a prescription medicine used to treat adults with type 2 diabetes. However, according to ASDA Online Doctor, it is also licensed for weight loss and manufactured by Eli Lilly.
READ MORE:
BOTH JEREMY CLARKSON AND AMY SCHUMER HAVE SWITCHED TO SAME WEIGHT LOSS DRUG
AMY SCHUMER SENDS MESSAGE TO FAMOUS ATHELE WHO PERFORMED SEX ACT ON HER
Long story short, it leads to better blood sugar control and weight reduction.
Taking to Instagram last week (9 April), she said in a video: "Hey, Amy here. I just wanted to say, again, I'm loving being on Mounjaro... am I saying that right? Mounjaro?"
"I haven't found it's affected anything, my meals are still very satisfying, and they give me a lot of energy," she said while eating food from a tiny bowl.
Schumer then joked that she was 'full' and started to laugh about it. The comments section was filled with many laughing emojis.
The comedian had previously opened up about her experience on Mounjaro, adding that it's 'been great'.
Adding that the drug is widely available in the US, she continued: "It's not covered by insurance unless you have diabetes or severe obesity, which most of the internet thinks I have, but I'm having a really good experience with it.
"I wanted to keep it real with you about that."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Lilly partners with Camurus in search of a long-lasting obesity drug
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Looking to defend its giant cardiometabolic health franchise, Eli Lilly is licensing a technology from Swedish biotechnology firm Camurus that promises to produce longer-acting medications. Camurus' FluidCrystal technology is designed to methodically release a therapeutic drug substance into the body over a period of days or months. After an injection, the solution interacts with bodily fluids to transform into a liquid crystalline gel. The gel holds the active ingredient and then slowly degrades, releasing medicine. The deal includes an unspecified upfront payment as part of an initial package that may be worth as much as $290 million, Camurus said Tuesday. That figure also includes payments for reaching certain development and regulatory milestones. Another $580 million could be available for meeting sales goals, along with mid-single digit royalties for successful products. Lilly and rival Novo Nordisk revolutionized diabetes and obesity treatment over the last few years with GLP-1 medicines that opened up one of the biggest markets the pharmaceutical industry has ever seen. In the first quarter alone, Lilly raked in more than $6 billion from sales of tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity. Novo brought in even more from its Ozempic and Wegovy. Now Lilly and Novo are faced with defending the market as a raft of competitors vie to offer newer and better options. Both companies have bulked up their pipelines; Lilly recently claimed success in a Phase 3 trial of a GLP-1 medicine that can be taken in pill form instead of injection. It also has a triple-acting drug in development and a number of other experimental medicines that work differently. The Camurus deal allows Lilly to apply the long-acting technology to as many as four of its drug compounds. That may help the company stave off competitors such as Metsera, which in January announced promising research for its experimental long-acting GLP-1 shot. Meanwhile, Roche recently announced a $1.65 billion deal to expand its obesity pipeline and Amgen and Viking Therapeutics are both moving into late-stage studies of potential rival treatments. Companies are also working on ways to augment the Lilly and Novo medicines. Veru is testing a drug designed to help preserve muscle when taken with Novo's Wegovy. Regeneron and others are conducting similar research. Recommended Reading Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs
Yahoo
3 hours ago
- Yahoo
Urgent call for south London blood donors amid 'slump' after bank holidays
NHS Blood and Transplant is asking South Londoners to help fill a donation shortfall caused by recent bank holidays. There are hundreds of appointments available at Brixton Donor Centre, with 1,000 slots needing to be filled each week to meet demand. The high number of bank holidays, combined with the start of the half-term break, has increased pressure on blood stocks. The NHS is particularly keen to see new and lapsed donors return. Brixton Donor Centre welcomes life-saving donors to South London (Image: NHS) Gerry Gogarty, director of blood supply at NHS Blood and Transplant, said: "The need for blood never stops. "We are extremely grateful to everyone who has donated so far this year, but we must act now to avoid falling behind. "To avoid facing a 'spring slump' in donations, we urgently need donors to book an appointment today – and help us fill appointments over the weeks ahead. "If you can't find an appointment straightaway, please book further ahead or keep checking back to help fill last-minute availability or cancellations. "Each donation has the power to save up to three lives." There is a particular need for donors of black heritage to meet the growing need for blood to treat sickle cell, the country's fastest-growing inherited blood disorder, which predominantly affects black communities. Black heritage donors are 10 times more likely than the white population to have the specific Ro blood type used to treat sickle cell patients. Around 1,300 black donors a month are needed to provide life-saving transfusions to sickle cell patients, as well as for use in emergencies, childbirth, during surgery, cancer treatments, and other medical conditions. Brixton Donor Centre, which opened in December 2024, has had 7 per cent of all donations with the in-demand Ro subtype, compared with 2 per cent nationally. South Londoners with O negative, O positive and A positive blood types are also being encouraged to donate, as these blood groups are in high demand. Brixton Blood Donor Centre manager Rexford Osei-Bonsu said: "I'm immensely proud of the thousands of people who have given blood in Brixton, but the holidays have meant that we need more people to come forward. "Giving blood is easy and painless and takes about an hour of your time to make a life-saving difference." Appointments can be made by calling 0300 123 2323 or visiting "We have the capacity to deliver more than 1,000 appointments a week and are happy to work round your availability, whether that's on your way to work, during your lunch break or as you head home."
New York Post
4 hours ago
- New York Post
Ozempic penis: Male users reveal shocking change to their genitalia after injecting weight-loss shot
It's the miracle drug that promises to shrink your size — except where it matters. Male Ozempic users say their penises have gotten bigger since they started injecting the weight-loss shot, with dozens of well-endowed fellas flocking to online forums to fawn over their expanded members. 'I recently measured myself down there and noticed I gained about one inch,' an anonymous user recently claimed on a Reddit thread. Advertisement 'Now I think people will say it was because of the fat loss. However at the time I measured myself before (4 years ago), I was thinner,' the man claimed. 'I also bone pressed during measurement before and also this time. Has anyone else noticed this change in themselves?' 3 Male Ozempic users say their penises have gotten bigger since they started injecting the weight-loss shot, with dozens of well-endowed fellas flocking to online forums to fawn over their expanded members. Shutterstock / Andrey_Popov 'Yes,' another happy Redditor responded. 'I gained 1.5 inches in length. No joke. Like you I obviously know how long I was before I got very fat. Then after about seven months on Tirzepatide in my case I gained 1.5 inches in length. Definitely not all from weight loss.' Advertisement 'I noticed that happen to me as well,' a third man remarked. 'Yeah, wife has definitely noticed a difference, was 278lbs down to under 200 lbs,' an additional commenter claimed. Meanwhile, other men also claimed that they had noticed a size difference after taking Ozempic, but put it down to better blood flow and reduced fat around the pubic area. Advertisement Another Redditor responded saying the size difference was likely due to different external conditions during the before and after measurements. 'I feel like nobody is really reading what you are writing, that they blame the weight loss while you measured the first time when you were actually lighter,' the explained. 'Ozempic does not enlarge your penis, but an erect penis may change size considerably depending on time of day, temperature, and factors other than sexual arousal. So it's probably just simply that.' 3 Some men also admitted that they had noticed a size difference after taking Ozempic, but put it down to better blood flow and reduced fat around the pubic area. myskin – Advertisement 3 Since it became widely available across America in 2024, users have reported an array of unexpected side effects. K KStock – The phenonemon — dubbed 'Ozempic penis' or 'Ozemd**k' — is just the latest in a series of side effects users of the weight-loss drugs have allegedly experencied. 'Ozempic mouth' is another recently reported side effect, marked by pronounced folds at the corners of the mouth, noticeable wrinkles on the lips, and sagging skin along the lip contours and chin area Those alarmed by their changed appearance are now turning to cosmetic treatments – such as dermal fillers – to restore lost volume around the mouth area.
